Wachovia Starts Bioenvision (BIVN) at Market Perform
More News related to BIVN
- Wachovia Starts Bioenvision (BIVN) at Market Perform
- Bioenvision (BIVN) Reports a Q4 Loss
- Bioenvision's (BIVN) Former General Counsel Files Action in NY Supreme Court Against the Company
- Genzyme (GENZ) Announces Completion of Tender Offer for Bioenvision
- Rodman & Renshaw Downgardes Bioenvision (BIVN) to Market Perform
More News related to GENZ
- Canaccord Adams Maintains a 'Buy' on Protalix BioTherapeutics (PLX); Cerezyme Supply on Track, See More Uplyso EAP Uptake
- Genzyme (GENZ) CEO Dumps 200K Shares As Company Deals With Manufacturing Issues
- InvestorSoup.com Issues Technical Trading Outlook for ARCA biopharma Inc.
- Morgan Joseph Reiterates a 'Buy' on Isis Pharmaceuticals (ISIS); Could Be Acquired by Potential Partners
- Piper Jaffray Maintains an 'Overweight' on ISIS Pharmaceuticals (ISIS); Price Target Cut
More News related to New Coverage
- Sprint Nextel (S) Completes Tender Offer for iPCS, Inc. (IPCS)
- Ford (F) and Geely Reportedly Clear Hurdle On Possible Volvo Deal
- Starent Networks (STAR) To Settle Shareholder Class Action Suit In Connection With Proposed Merger with Cisco (CSCO)
- Hurray! Holding (HRAY) To Acquire Ku6 in All Stock Transaction
Wachovia initiates coverage on Bioenvision Inc. (Nasdaq: BIVN) with a Market Perform rating and $5.60-$7 valuation range. The firm said the outcome of the shareholder vote on the merger with Genzyme (Nasdaq: GENZ) is uncertain.
Related Categories
New CoverageStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
